Journal for ImmunoTherapy of Cancer (Jul 2024)
Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3
Abstract
No abstracts available.
